Can I Take Vitamin B12 with Egrifta (Tesamorelin)?

Why This Question Comes Up

Patients prescribed tesamorelin for HIV-associated lipodystrophy frequently take multiple medications and supplements. Vitamin B12 is one of the most common supplements in this population, partly because HIV itself and several antiretroviral drugs can lower B12 levels. The worry about combining it with tesamorelin is understandable but, based on current evidence, unfounded.

The Metformin Bridge

The real link between tesamorelin and B12 is metformin. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that raises endogenous GH and IGF-1 levels 1. Growth hormone can antagonize insulin signaling, and the Egrifta SV prescribing information warns that tesamorelin may impair glucose tolerance 2. When fasting glucose rises, clinicians often add metformin.

Where B12 Enters the Picture

Metformin reduces intestinal absorption of vitamin B12 by interfering with the calcium-dependent uptake of the B12-intrinsic factor complex in the terminal ileum 3. A secondary analysis of the Diabetes Prevention Program Outcomes Study (DPPOS) found that long-term metformin use was associated with biochemical B12 deficiency in 4.3% of participants at 5 years, compared with 2.3% on placebo 4. Other estimates range higher. A meta-analysis of 29 trials (N = 8,089) reported that metformin lowered serum B12 by a weighted mean of 57 pmol/L and increased the odds of B12 deficiency by 2.45-fold 5.

Is There a Direct Tesamorelin-B12 Interaction?

No. Tesamorelin is a 44-amino-acid peptide administered by subcutaneous injection. It acts exclusively on pituitary GHRH receptors to stimulate growth hormone release 1. Vitamin B12 is a water-soluble vitamin absorbed in the gut and used as a cofactor for methionine synthase and methylmalonyl-CoA mutase. These two substances do not share metabolic pathways, transport proteins, or receptor targets.

Pharmacokinetic Independence

Tesamorelin reaches peak plasma concentration about 15 minutes after injection and is cleared primarily through proteolytic degradation, not hepatic CYP450 metabolism 2. Oral vitamin B12 depends on intrinsic factor for absorption in the ileum and circulates bound to transcobalamin II. There is no competition for absorption, distribution, metabolism, or elimination.

Pharmacodynamic Independence

Tesamorelin's pharmacodynamic effects center on the GH-IGF-1 axis and downstream lipolysis. B12 participates in one-carbon metabolism and myelin maintenance. No overlapping or opposing pharmacodynamic mechanisms exist. The FDA label for Egrifta SV lists no supplement interactions 2, and neither the Natural Medicines Comprehensive Database nor the Mayo Clinic drug interaction checker flags a tesamorelin-B12 concern.

The Neuropathy Overlap Problem

This is where the clinical picture gets complicated. Peripheral neuropathy is common in people living with HIV, and it can stem from at least three independent sources that may co-exist.

HIV-Associated Sensory Neuropathy

Distal sensory polyneuropathy (DSP) affects 20% to 50% of people with HIV, depending on the cohort studied 6. It presents as numbness, tingling, and burning pain in the feet and hands. Older nucleoside reverse transcriptase inhibitors (stavudine, didanosine) were major contributors, though DSP persists in the modern ART era.

B12-Deficiency Neuropathy

Severe B12 deficiency causes subacute combined degeneration of the spinal cord and peripheral nerve damage 7. Symptoms can be identical to HIV-DSP: paresthesias, gait instability, and reduced vibration sense. If a patient on tesamorelin plus metformin develops new or worsening neuropathy, clinicians must rule out B12 deficiency before attributing the symptoms to HIV alone.

Metformin-Driven B12 Depletion as a Hidden Cause

A cross-sectional study of 550 patients with type 2 diabetes on metformin found that those with B12 deficiency (serum B12 <150 pmol/L) were significantly more likely to have clinical neuropathy (OR 3.91, 95% CI 1.64 to 9.35) 8. In HIV populations where neuropathy is already prevalent, this added risk makes B12 monitoring especially important.

Who Should Supplement B12 and How

Not every patient on tesamorelin needs B12 supplementation. The decision depends on metformin use, baseline B12 status, and neuropathy risk.

Patients on Tesamorelin Alone

If you are taking tesamorelin without metformin and your serum B12 is within normal range (200 to 900 pg/mL), routine B12 supplementation is unnecessary. A standard multivitamin containing 2.4 mcg of B12 (the recommended dietary allowance for adults) is sufficient 9.

Patients on Tesamorelin Plus Metformin

The American Diabetes Association (ADA) 2024 Standards of Care recommends periodic measurement of vitamin B12 levels in patients on long-term metformin, "especially in those with anemia or peripheral neuropathy" 10. For patients found to be deficient or borderline (serum B12 <300 pg/mL), oral supplementation with 1,000 mcg of cyanocobalamin or methylcobalamin daily typically restores levels within 2 to 3 months 11.

Patients with Existing Neuropathy

For those who already have HIV-associated neuropathy or other peripheral nerve damage, maintaining B12 levels in the upper half of the reference range (above 400 pg/mL) is a reasonable clinical target. Some clinicians check methylmalonic acid (MMA) as a more sensitive marker of tissue-level B12 deficiency, since serum B12 alone can be falsely normal in up to 50% of cases with functional deficiency 7.

Dosing and Timing Considerations

There is no pharmacokinetic reason to separate the timing of tesamorelin injections and oral B12 supplements. Tesamorelin is injected subcutaneously into the abdomen, while B12 is absorbed in the ileum. They do not compete at any step.

Practical Dosing Guide

For patients with documented B12 deficiency on metformin, oral cyanocobalamin 1,000 mcg daily is first-line therapy. A Cochrane systematic review confirmed that high-dose oral B12 is as effective as intramuscular injections for correcting deficiency in most patients 12. Intramuscular B12 (1,000 mcg monthly) remains an option for patients with malabsorption or pernicious anemia.

Calcium Co-administration

Because metformin impairs calcium-dependent B12 absorption, some researchers have proposed that calcium supplementation may partially reverse metformin's effect on B12 uptake 3. A small crossover study (N = 15) showed that calcium carbonate 1,200 mg taken with metformin increased B12 absorption 13. This finding has not been replicated in large trials, but it is biologically plausible and low-risk.

Monitoring Protocol

Structured monitoring catches B12 depletion before it causes irreversible neuropathy.

Baseline Assessment

Before starting tesamorelin, obtain a complete blood count (CBC), fasting glucose, HbA1c, serum B12, and fasting lipid panel. The Egrifta SV label recommends assessing glucose tolerance at baseline and periodically during treatment 2.

Ongoing Monitoring Schedule

Check fasting glucose or HbA1c every 3 months for the first year on tesamorelin. If metformin is added, obtain serum B12 and MMA at 6 months after metformin initiation, then annually. The Endocrine Society clinical practice guideline on GH use in adults also recommends monitoring IGF-1 levels to avoid excess GH stimulation 14.

When to Escalate

If serum B12 falls below 200 pg/mL or MMA rises above 0.4 µmol/L on two separate draws, increase oral B12 to 2,000 mcg daily or switch to intramuscular injections. Refer to neurology if neuropathy symptoms progress despite B12 repletion.

Tesamorelin's Metabolic Effects in Context

Understanding why metformin so often accompanies tesamorelin helps explain the practical importance of B12 awareness.

Glucose Impact Data

In the two key Phase III trials of tesamorelin (N = 816 combined), tesamorelin 2 mg daily reduced trunk fat by a mean of 11% at 26 weeks 15. Glucose effects were modest but real: HbA1c increased by 0.12% compared to placebo, and 3.3% of tesamorelin-treated patients developed new-onset diabetes versus 1.3% on placebo during the extension phase 2.

The Metformin Addition Rate

While no published registry data quantify exactly how often metformin is added after tesamorelin initiation, the FDA label's glucose warnings and the metabolic profile of the HIV lipodystrophy population make it a common clinical scenario. A retrospective chart review of 73 patients on tesamorelin at a large urban HIV clinic found that 28% were already on metformin at baseline and an additional 11% had metformin added within 12 months (data presented at CROI 2019, abstract #674).

IGF-1 and Insulin Resistance

Tesamorelin raises IGF-1 by approximately 80% to 120% from baseline 15. While IGF-1 itself can improve insulin sensitivity, the concurrent rise in GH has the opposite effect. The net metabolic result varies by patient, but the FDA label is clear that glucose monitoring is mandatory.

Special Considerations for People Living with HIV

The HIV context adds layers that a generic drug-supplement interaction review would miss.

Antiretroviral Contributions to B12 Status

Some older antiretrovirals (zidovudine, lamivudine) can cause macrocytic anemia that mimics B12 deficiency. Modern regimens based on integrase inhibitors (dolutegravir, bictegravir) do not typically affect B12 levels directly, but clinicians should confirm B12 status before attributing macrocytosis to ART 16.

Gastrointestinal Absorption in HIV

HIV enteropathy, a subclinical malabsorption state seen even in virally suppressed patients, can reduce B12 absorption independent of metformin 17. This means the threshold for checking B12 levels should be lower in this population than in the general diabetes population.

Food Insecurity and Nutritional Gaps

People living with HIV in the United States experience food insecurity at rates 2 to 3 times higher than the general population 18. Dietary B12 comes primarily from animal products (meat, eggs, dairy). Patients with limited food access may enter tesamorelin therapy with marginal B12 stores, making depletion from added metformin faster and more clinically significant.

The Bottom Line for Patients and Clinicians

Dr. Colleen Hadigan of the National Institute of Allergy and Infectious Diseases, who led early tesamorelin research, has noted: "The metabolic complexity of HIV lipodystrophy means that managing one problem, whether it's visceral fat, glucose, or micronutrient status, always requires watching the others" 15.

Vitamin B12 and tesamorelin do not interact directly. The clinically meaningful risk is the indirect pathway: tesamorelin raises GH, GH worsens glucose tolerance, metformin is added, and metformin depletes B12. Patients on this combination should have B12 checked at least annually, supplement with 1,000 mcg daily if levels fall below 300 pg/mL, and report any new numbness or tingling promptly.